Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6485

Provisional Schedule

Committee meeting 14 October 2025
Expected publication 17 December 2025

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Stakeholders

Companies sponsors Genus Pharmaceuticals (targeted-release budesonide)
Others Department of Health and Social Care
  NHS England
Patient carer groups Kidney Care UK
  Kidney Research UK
  National Kidney Federation
  Polycystic Kidney Disease Charity
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of Renal Technologists
  British Association of Urological Nurses
  British Geriatrics Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for DGH Nephrologists
  UK Clinical Pharmacy Association
  UK Kidney Association
  UK Renal Pharmacy Group
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies A.Menarini Group (canagliflozin)
  Advanz pharma (acetazolamide)
  Amarox (eprosartan, irbesartan, losartan, olmesartan)
  AS Kalceks (furosemide)
  AstraZeneca (dapagliflozin)
  Atnahs pharma (chlortalidone, lisinopril)
  Aurobindo pharma (amiloride hydrochloride, candesartan, enalapril, furosemide, fosinopril, irbesartan, lisinopril, losartan, olmesartan, perindopril, ramipril, valsartan)
  Baxter healthcare ( furosemide)
  Boehringer Ingelheim (empagliflozin, telmisartan)
  Bristol laboratories (lisinopril)
  Brown & Burk (irbesartan, lisinopril, ramipril, telmisartan, losartan)
  Chemidex pharma (amiloride hydrochloride, bumetanide)
  Daiichi Sankyo (olmesartan)
  Dexcel pharma (enalapril, losartan)
  Essential pharma (amiloride hydrochloride)
  Flamingo Pharma (losartan)
  Glenmark pharma (olmesartan, perindopril, telmisartan)
  Hameln pharma (furosemide)
  Ipca laboratories (furosemide)
  KrKA UK (candesartan, indapamide, losartan, olmesartan, perindopril, telmisartan)
  Martindale pharma (captopril)
  Merck Sharp & Dohme (ertugliflozin)
  Morningside healthcare (chlortalidone)
  Neon healthcare (candesartan)
  Novartis (valsartan)
  Organon Pharma (enalapril, losartan)
  Pfizer (quinapril)
  Phoenix healthcare (quinapril)
  Pinewood healthcare (furosemide)
  Proveca (enalapril)
  Roma pharmaceuticals (lisinopril, ramipril)
  Rosemont pharmaceuticals (bumetanide, enalapril, furosemide, lisinopril, ramipril)
  Sandoz (candesartan, losartan, perindopril, ramipril, telmisartan)
  Sanofi (furosemide, irbesartan, ramipril)
  Servier laboratories (indapamide, perindopril)
  Sigma pharmaceuticals (amiloride hydrochloride, bendroflumethiazide, chlortalidone, indapamide, quinapril)
  Strides pharma (furosemide, indapamide)
  Takeda (azilsartan)
  Ten pharma (captopril)
  Thame laboratories (captopril, furosemide)
  Thornton & Ross (olmesartan)
  Tillomed laboratories (amiloride hydrochloride, perindopril,)
  Viatris (bendroflumethiazide, bumetanide, candesartan, enalapril, eprosartan, indapamide, irbesartan, lisinopril, losartan, perindopril, torasemide, trandolapril, valsartan, xipamide)
  Vifor Pharma (sparsentan)
  Wockhardt UK (amiloride hydrochloride, captopril, chlortalidone, furosemide, ramipril)
  Zentiva (indapamide, irbesartan, ramipril, valsartan)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Association of Renal Industries
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  NHS Wales Joint Commissioning Committee
  Scottish Medicines Consortium
  Welsh Government
Relevant research groups Cochrane Kidney and Transplant Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
14 March 2025 Invitation to participate
24 January 2025 - 07 February 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 January 2025 In progress. Scope consultation.
12 December 2024 Referral
03 December 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual